Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormon
First EU approval for fulvestrant in combination with a CDK4/6 inhibitor Fu...
2017-11-17
文传商讯
FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT
Positive opinion is based on Phase III trial data demonstrating a 4.9 month ...
2017-10-17
文传商讯
Faslodex Demonstrates Progression-Free Survival Advantage in 1st Line A
Faslodex reduces risk of progression by 20% and extends median progression-f...
2016-10-11
文传商讯
